Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?